Douglas J. Schwartzentruber

Best Publications

• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  3729
  Citations

• A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

  James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  3529
  Citations

• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  3335
  Citations

• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  2270
  Citations

• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  1911
  Citations

• Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

  Steven A. Rosenberg;John R. Yannelli;James C. Yang;Suzanne L. Topalian

  1313
  Citations

• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  Douglas J. Schwartzentruber;David H. Lawson;Jon M. Richards;Robert M. Conry

  1097
  Citations

• Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

  James C. Yang;Richard M. Sherry;Seth M. Steinberg;Suzanne L. Topalian

  1001
  Citations

• Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

  Steven A. Rosenberg;Michael T. Lotze;James C. Yang;Suzanne L. Topalian

  817
  Citations

• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  Steven A. Rosenberg;Richard M. Sherry;Kathleen E. Morton;William J. Scharfman;William J. Scharfman

  559
  Citations

• Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

  Mark E. Dudley;John Wunderlich;Michael I. Nishimura;David Yu

  540
  Citations

• A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

  Mark E. Dudley;John R. Wunderlich;James C. Yang;Patrick Hwu

  524
  Citations

• Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

  Sharilyn K. Stanley;Mario A. Ostrowski;Jesse S. Justement;Kira Gantt

  430
  Citations

• Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b

  Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  419
  Citations

• Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens

  Steven A. Rosenberg;Yifan Zhai;James C. Yang;Douglas J. Schwartzentruber

  387
  Citations

• Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

  Joseph A. Kovacs;Richard A. Lempicki;Igor A. Sidorov;Joseph W. Adelsberger

  275
  Citations

• A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames

  Rong Fu Wang;Samuel L. Johnston;Gang Zeng;Suzanne L. Topalian

  267
  Citations

• High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

  Janice P Dutcher;Douglas J Schwartzentruber;Howard L Kaufman;Sanjiv S Agarwala

  227
  Citations

• Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.

  J C Yang;S L Topalian;D Parkinson;D J Schwartzentruber

  223
  Citations

• In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

  Douglas J. Schwartzentruber;Sophia S. Hom;Roya Dadmarz;Donald E. White

  222
  Citations